Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on May 12, 2025
EchoFree Under Review: The Brain Wire Army Hack Silences Ear Ringing Tinnitus for Good
GlobeNewswire
·
May 12, 2025
New York, May 12, 2025 (GLOBE NEWSWIRE) -- In This Article, You'll Discover What EchoFree is and how the Brain Wire Army Hack aims to support ear health and reduce tinnitus symptoms How EchoFree Drops may help with ringing or buzzing in the ears as part of …
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
GlobeNewswire
·
May 12, 2025
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide …
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context …
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
GlobeNewswire
·
May 12, 2025
KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). Obesity-associated cardiometabolic preclinical …
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in …
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX- …
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire
·
May 12, 2025
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and …
Vireo Growth Inc. Announces Closing of WholesomeCo Cannabis & Arches Merger Transactions
GlobeNewswire
·
May 12, 2025
– Acquisitions strengthen profitability and competitive position with proprietary technology platform – – Missouri and Nevada transactions remain on track to close during the second quarter of 2025 – MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Vireo …
Cellectis Reports Financial Results for the First Quarter 2025
GlobeNewswire
·
May 12, 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …
Editas Medicine Announces First Quarter 2025 Results and Business Updates
GlobeNewswire
·
May 12, 2025
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo …
Stran & Company Schedules First Quarter 2025 Financial Results and Business Update Conference Call
GlobeNewswire
·
May 12, 2025
Quincy, MA, May 12, 2025 (GLOBE NEWSWIRE) -- Stran …
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
GlobeNewswire
·
May 12, 2025
FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a …
ODDITY Announces Block Trade of Class A Ordinary Shares
GlobeNewswire
·
May 12, 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (the “Company”) (NASDAQ: ODD) today announced the sale of 5,500,000 shares of its Class A ordinary shares by an entity affiliated with Oran Holtzman, ODDITY co-founder and CEO. The transaction …
SlimBliss Under Review: Simple Coffee Hack Loophole to Lose Weight with Slim Bliss MCT Coffee Creamer
GlobeNewswire
·
May 12, 2025
New York, May 12, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: An In-Depth Review of SlimBliss™ MCT Coffee Creamer: Explore how this mocha-flavored supplement integrates into daily routines to support weight management goals. Key Ingredients …
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b …
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 12, 2025
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in …
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European …
Maravai Lifesciences Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first …
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025 Cash, …
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 12, 2025
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise …